Literature DB >> 14671811

[Therapy of hyperlipoproteinemia in the elderly].

K G Parhofer1, B Göke.   

Abstract

Atherosclerosis associated diseases are the major cause of mortality in men and women over 65 years. Although the epidemiological relationship between hypercholesterolemia and cardiovascular disease is less prominent in elderly than in younger patients, the results of numerous intervention trials show that risk reduction can also be achieved in elderly and old patients. The numbers needed to treat to prevent one cardiovascular event is usually lower in this age group because of the high absolute rate of events. Therefore, in secondary prevention settings these patients should be treated similar to younger patients, i.e. a LDL-cholesterol below 100 mg/dl should be achieved. In hyper- or dyslipoproteinemic patients without evidence of clinical or subclinical atherosclerosis cholesterol lowering drugs should be used restrictively.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14671811     DOI: 10.1007/s00108-003-0942-4

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  32 in total

1.  C-reactive protein--to screen or not to screen?

Authors:  Lori Mosca
Journal:  N Engl J Med       Date:  2002-11-14       Impact factor: 91.245

2.  Overall and coronary heart disease mortality rates in relation to major risk factors in 325,348 men screened for the MRFIT. Multiple Risk Factor Intervention Trial.

Authors:  W B Kannel; J D Neaton; D Wentworth; H E Thomas; J Stamler; S B Hulley; M O Kjelsberg
Journal:  Am Heart J       Date:  1986-10       Impact factor: 4.749

3.  Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis.

Authors: 
Journal:  JAMA       Date:  2002 Oct 23-30       Impact factor: 56.272

4.  Inhibition of intestinal cholesterol absorption by ezetimibe in humans.

Authors:  Thomas Sudhop; Dieter Lütjohann; Annette Kodal; Michael Igel; Diane L Tribble; Sukrut Shah; Inna Perevozskaya; Klaus von Bergmann
Journal:  Circulation       Date:  2002-10-08       Impact factor: 29.690

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Predicting coronary heart disease in middle-aged and older persons. The Framington study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  JAMA       Date:  1977-08-08       Impact factor: 56.272

7.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

8.  Determinants of the increase of serum cholesterol with age: a longitudinal study.

Authors:  M A Berns; J H de Vries; M B Katan
Journal:  Int J Epidemiol       Date:  1988-12       Impact factor: 7.196

9.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245

10.  Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial.

Authors:  Guido Schnyder; Marco Roffi; Yvonne Flammer; Riccardo Pin; Otto Martin Hess
Journal:  JAMA       Date:  2002-08-28       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.